ライフサイエンスコーパス: misoprostol

1 l infusion of a prostaglandin E(1) analogue (misoprostol).

2 of participants chose home administration of misoprostol.

3 was stimulated chemokinetically by PGE2 and misoprostol.

4 measured at 1 week and 3 weeks after taking misoprostol.

5 oxytocin would be preferred over sublingual misoprostol.

6 one followed 24 to 48 hours later by vaginal misoprostol.

7 nts or the synthetic prostaglandin analogue, misoprostol.

8 c and then chose whether to take 400 mg oral misoprostol 2 days later either at home or in the clinic

9 to receive labour induction with either oral misoprostol 25 mug every 2 h (maximum of 12 doses) or a

10 e and misoprostol (357 women) or placebo and misoprostol (354 women).

11 assigned to receive either mifepristone and misoprostol (357 women) or placebo and misoprostol (354

12 one, 600 mg orally, followed 2 days later by misoprostol, 400 microg orally (within 49 days from last

13 Misoprostol 600 microg is inferior to oxytocin 10 IU for

14 Of the 491 women assigned to receive misoprostol, 71 percent had complete expulsion by day 3

15 single dose of vaginal, oral, or sublingual misoprostol 800 mug 2 days later.

16 e, 200 mg orally, followed in 1 to 3 days by misoprostol, 800 microg vaginally (up to 63 days).

17 Our results suggest that vaginal misoprostol, 800 microg, can be used from 1 to 3 days af

18 Mifepristone, 200 mg, and misoprostol, 800 ug, prescribed to a mail-order pharmacy

19 Fifty-five subjects aborted before taking misoprostol, 9 had early surgery, and 103 did not take m

20 Treatment of COX-2(-/-) mice with misoprostol (a PGE(1/2) analog) or beraprost (a PGI(2) a

21 Treatment with misoprostol, a clinically available PGE analogue, improv

22 Misoprostol, a PGE1 analog, was developed as an antiulce

23 We aimed to investigate whether oral misoprostol, a potential alternative to oxytocin, could

24 Misoprostol, a potential alternative, is increasingly us

25 Mifepristone-misoprostol abortion, consisting of oral pills, is poten

26 The conventional timing of misoprostol administration after mifepristone for medica

27 2006 Planned Parenthood changed the route of misoprostol administration from vaginal to buccal and re

28 infections were associated with intravaginal misoprostol administration, suggesting that high misopro

29 ce interval [CI], 97%-99%) among those using misoprostol after 1 day, 98% (95% CI, 97%-99%) for those

30 us adverse events occurred: 6 in those using misoprostol after 1 day; 4 in those using it after 2 day

31 1 day, 98% (95% CI, 97%-99%) for those using misoprostol after 2 days, and 96% (95% CI, 95%-97%) amon

32 and 96% (95% CI, 95%-97%) among those using misoprostol after 3 days.

33 cent of the women stated that they would use misoprostol again if the need arose and 83 percent state

34 follow-up self-managed their abortions using misoprostol alone (593 participants) or the combined reg

35 estricted to participants who reported using misoprostol alone and was performed between January 6, 2

36 tone plus misoprostol is more effective than misoprostol alone but is underutilized in the US.

37 strategies to maximize the effectiveness of misoprostol alone in clinical and nonclinical settings.

38 one plus misoprostol was more effective than misoprostol alone in the management of missed miscarriag

39 The findings suggest that misoprostol alone is a highly effective method of pregna

40 Before using one of two medication regimens (misoprostol alone or in combination with mifepristone),

41 At last follow-up, 586 (99%) misoprostol alone users and 334 (94%) combined regimen u

42 ge EPL (ie, mifepristone plus misoprostol or misoprostol alone).

43 pristone plus misoprostol and 97.0% received misoprostol alone.

44 Self-managed medication abortion using misoprostol alone.

45 mpletion of missed miscarriage compared with misoprostol alone.

46 prostol is more effective than administering misoprostol alone.

47 Among 1352 enrolled participants, 637 used misoprostol-alone regimens for abortion and were include

48 Misoprostol-alone regimens for abortion may be more effe

49 Misoprostol also reduced TNF-alpha production within the

50 Misoprostol, an effective uterotonic agent with several

51 four E-prostanoid (EP) receptor subtypes and misoprostol, an EP2 and EP4 agonist, increased MUC5AC pr

52 Misoprostol, an EP3 agonist, inhibited glucose-induced i

53 Misoprostol, an FDA-approved EP4 agonist, conferred simi

54 piration to empty the uterus, and the use of misoprostol, an oxytocic agent, have improved the care o

55 tment occurred for 139 (34%) women receiving misoprostol and 123 (31%) receiving oxytocin (RR 1.12, 9

56 initial treatment for 363 (89%) women given misoprostol and 360 (90%) given oxytocin (relative risk

57 dy treatment alone for 440 (90%) women given misoprostol and 468 (96%) given oxytocin (relative risk

58 nt occurred for 147 (30%) of women receiving misoprostol and 83 (17%) receiving oxytocin (RR 1.78, 95

59 se patients, 3.0% received mifepristone plus misoprostol and 97.0% received misoprostol alone.

60 s after a change to buccal administration of misoprostol and after initiation of additional infection

61 Community provision of misoprostol and antibiotics to reduce maternal deaths fr

62 o and in vitro experiments demonstrated that misoprostol and beraprost acted directly on hepatic leuk

63 terine hyperstimulation were low in both the misoprostol and Foley catheter groups (two [0.7%] vs one

64 e antigen exposures over a 3-wk period, both misoprostol and its free acid-active metabolite 5C-30695

65 ed in Senegal outside health facilities, and misoprostol and oxytocin delivered via Uniject have been

66 20 (3.6%) and 15 (2.7%) participants in the misoprostol and oxytocin groups, respectively (RR 1.33,

67 432.8 ml (SD 203.5, p<0.001) at 24 h in the misoprostol and oxytocin groups, respectively.

68 Nebulizied solutions of misoprostol and PGE2 effectively blocked the acute bronc

69 ay resistance was 3 and 30 micrograms/ml for misoprostol and PGE2, respectively.

70 d for four hours after the administration of misoprostol and returned on day 15 for final assessment.

71 ion services is changing to include the drug misoprostol and this could reduce the severity of aborti

72 nt change to buccal misoprostol from vaginal misoprostol and to either testing for sexually transmitt

73 icantly by 10(-9) to 10(-7) M PGE2, 10(-6) M misoprostol, and 10(-4) M dibutyryl cyclic AMP, but not

74 ication abortion (such as aspiration, repeat misoprostol, and blood transfusion), frequency of contin

75 ncentration of cyclic AMP ([cAMP]i) by PGE2, misoprostol, and butaprost and of increases in the intra

76 3/EP2/EP4 R-selective agonists M&B 28767 and misoprostol, and EP2 R-selective agonist butaprost but n

77 2, PGE2 methyl ester, misoprostol-free acid, misoprostol, and sulprostone suggested that a negative c

78 ge, medical management with mifepristone and misoprostol, and surgical management with manual vacuum

79 in, carbetocin, carboprost, ergot alkaloids, misoprostol, and tranexamic acid were included in the fi

80 exposures in early pregnancy - thalidomide, misoprostol, and valproic acid; maternal rubella infecti

81 ned to self-administer 800 microg of vaginal misoprostol at home 1 (n = 745), 2 (n = 778), or 3 (n =

82 ction rates were higher among those who used misoprostol at home.

83 s group took 200 mg mifepristone and 800 mug misoprostol at home.

84 ok 200 mg mifepristone in clinic and 800 mug misoprostol at home.

85 15 years or older, and were willing to take misoprostol buccally.

86 nist M&B 28767, and the EP2/EP4/EP3R agonist misoprostol but not by the EP1R antagonist SC-19220 or t

87 )-10(-6) M PGE2, sulprostone, M&B 28767, and misoprostol but not with 10(-6) M PGF2alpha, PGD2, PGI2,

88 ssion was confirmed by finding that PGE2 and misoprostol, but not butaprost or sulprostone, evoked in

89 sess whether oxytocin augmentation following misoprostol can be replaced by regular doses of oral mis

90 rone drug mifepristone and the prostaglandin misoprostol can be used to treat missed miscarriage.

91 nge from vaginal to buccal administration of misoprostol combined with routine administration of anti

92 prostol administration, suggesting that high misoprostol concentrations within the uterus impair immu

93 shelf life outside the cold chain, mean that misoprostol could be more appropriate for community-leve

94 Subcutaneous injection of the PGE(2) analog misoprostol decreased M-CSFR expression in bone marrow c

95 The intrauterine injection of misoprostol did not enhance mortality from infection by

96 tervention in both periods was an additional misoprostol dose and was most commonly administered to t

97 P2(-/-) mice, subcutaneous administration of misoprostol during sensitization inhibited allergic infl

98 and EP1/3 (sulprostone) mimicked PGE2, while misoprostol (E1-4) actually enhanced the action of CM.

99 Data are also reviewed demonstrating that misoprostol effectively decreased significant poor gastr

100 The effects of non-selective (PGE2 , misoprostol), EP2 -selective (ONO-AE1-259, AH13205, buta

101 Administration of misoprostol exacerbated collagen-induced arthritis (CIA)

102 tion and three-step treatment strategy using misoprostol, followed if needed by an intrauterine condo

103 rotocol for mifepristone, which is used with misoprostol for medication abortion.

104 hat had been included in a previous study of misoprostol for prevention of postpartum haemorrhage wer

105 tition binding with PGE2, PGE2 methyl ester, misoprostol-free acid, misoprostol, and sulprostone sugg

106 gnificantly after the joint change to buccal misoprostol from vaginal misoprostol and to either testi

107 us 87 (25%) of 353 women in the placebo plus misoprostol group (0.71, 0.53-0.95; p=0.021).

108 us 82 (24%) of 348 women in the placebo plus misoprostol group (risk ratio [RR] 0.73, 95% CI 0.54-0.9

109 ut clusters were randomly assigned-14 to the misoprostol group and 14 to the oxytocin group.

110 concentrations was 3.5 g/L (SD 16.1) in the misoprostol group and 2.7 g/L (SD 17.8) in the oxytocin

111 Treatment failed in 16 percent of the misoprostol group and 3 percent of the surgical group (a

112 647 women in the misoprostol group and 402 in the oxytocin group received

113 occurred in 163 (28.6%) participants in the misoprostol group and 99 (17.4%) participants in the oxy

114 group) and eight neonatal deaths (n=5 in the misoprostol group and n=3 in the Foley catheter group);

115 (17%) of 348 women in the mifepristone plus misoprostol group did not pass the gestational sac spont

116 Women in the misoprostol group more commonly experienced shivering (R

117 The misoprostol group received treatment on day 1, a second

118 (17%) of 355 women in the mifepristone plus misoprostol group required surgical intervention to comp

119 within 24 h was more common in women in the misoprostol group than in the Foley catheter group (172

120 Surgical treatment (for the misoprostol group) or repeated aspiration (for the vacuu

121 In the misoprostol group, 78 percent of the women stated that t

122 Shivering was common in the misoprostol group, and nausea in the oxytocin group.

123 Women taking misoprostol had a higher rate of transitory symptoms of

124 dvantages over other uterotonics, the use of misoprostol has been increasing, especially in resource-

125 Little is known about the effect inhaled misoprostol has on the airway and whether its potential

126 eatment of diabetic mice with the PGE analog misoprostol improved host defense against MRSA skin infe

127 d within 4 hours after the administration of misoprostol in 49 percent of the women and within 24 hou

128 ts of a large U.S. study of mifepristone and misoprostol in women with pregnancies of up to nine week

129 New treatment regimens for decreasing misoprostol-induced toxicity are also reviewed.

130 Misoprostol is a pharmacomimetic of PGE(2), an endogenou

131 Misoprostol is clinically equivalent to oxytocin when us

132 Misoprostol is increasingly used to treat women who have

133 ar whether a combination of mifepristone and misoprostol is more effective than administering misopro

134 Combination treatment with mifepristone plus misoprostol is more effective than misoprostol alone but

135 This trial established whether sublingual misoprostol is non-inferior to intravenous oxytocin for

136 tion, with a combination of mifepristone and misoprostol, is highly effective and safe.

137 i-inflammatory effects suggests that inhaled misoprostol may be an effective treatment for the acute

138 The mifepristone-misoprostol medication abortion regimen became available

139 gs in which use of oxytocin is not feasible, misoprostol might be a suitable first-line treatment alt

140 rbetocin monotherapy, 1773 patients received misoprostol monotherapy, and 100 patients received carbo

141 andomly assigned 602 women to induction with misoprostol (n=302) or the Foley catheter (n=300; intent

142 nd were randomly assigned to receive 800 mug misoprostol (n=407) or 40 IU intravenous oxytocin (n=402

143 were randomly assigned to receive 800 microg misoprostol (n=488) or 40 IU intravenous oxytocin (n=490

144 rural India were randomised to receive oral misoprostol (n=812) or placebo (n=808) after delivery.

145 l, 9 had early surgery, and 103 did not take misoprostol on their assigned day.

146 available for medical abortion (for use with misoprostol) only with Risk Evaluation and Mitigation St

147 uity Health Projects) to either 600 mug oral misoprostol or 10 IU oxytocin in Uniject (intramuscular)

148 on used to manage EPL (ie, mifepristone plus misoprostol or misoprostol alone).

149 Their place in therapy, compared with use of misoprostol or proton pump inhibitors, is currently emer

150 tion after 200 mg mifepristone and 1,600 mug misoprostol (or lower) without additional intervention;

151 bortion), the increasingly widespread use of misoprostol outside formal health systems in contexts wh

152 Differences favoring diclofenac + misoprostol over acetaminophen were greater in patients

153 more common when patients took diclofenac + misoprostol (P = 0.046).

154 parative efficacy of oxytocin and sublingual misoprostol, particularly at the recommended dose of 600

155 593 participants) or the combined regimen of misoprostol plus mifepristone (356 participants).

156 amic acid plus oxytocin (n=5331) followed by misoprostol plus oxytocin.

157 se complications have been demonstrated with misoprostol, proton pump inhibitors (PPIs) (only documen

158 ministration-approved prostaglandin E analog misoprostol reduces tissue injury and enhances bacterial

159 o simplifications to the French mifepristone-misoprostol regimen in Vietnam and Tunisia.

160 This mifepristone-misoprostol regimen is effective in terminating pregnanc

161 the need for repeating the mifepristone and misoprostol regimen or a follow-up procedure, and safety

162 owed by the option of home administration of misoprostol seems feasible.

163 uterine but not the intragastric delivery of misoprostol significantly worsened mortality from C. sor

164 Exposure to a 300 micrograms/ml nebulized misoprostol solution provided significant protection for

165 domized 1,140 women to receive 600 microg of misoprostol sublingually or 10 IU of oxytocin intramuscu

166 In vitro, misoprostol suppressed macrophage TNF-alpha and chemokin

167 Two low-cost interventions-low-dose oral misoprostol tablets and transcervical Foley catheterisat

168 tol can be replaced by regular doses of oral misoprostol tablets.

169 primary outcomes were seen for diclofenac + misoprostol than for acetaminophen (P < 0.001).

170 n pain scores over 6 weeks with diclofenac + misoprostol than with acetaminophen, although patients w

171 09-1.99) were significantly more common with misoprostol than with oxytocin.

172 52-11.8) were significantly more common with misoprostol than with oxytocin.

173 be offered mifepristone pretreatment before misoprostol to increase the chance of successful miscarr

174 estimulation, draining lymph node cells from misoprostol-treated mice secreted higher levels of IL-17

175 of two groups, 75 mg diclofenac + 200 microg misoprostol twice daily or 1,000 mg acetaminophen 4 time

176 00 mg of mifepristone and then 400 microg of misoprostol two days later to 2121 women seeking termina

177 mends use of oxytocin for prevention of PPH, misoprostol use is increasingly common owing to advantag

178 f early pregnancy failure with 800 microg of misoprostol vaginally is a safe and acceptable approach,

179 e randomly assigned to receive 800 microg of misoprostol vaginally or to undergo vacuum aspiration (s

180 The PGE2 analog misoprostol was administered during sensitization in bot

181 A second dose of misoprostol was administered if the abortion was not com

182 on after medical abortion during a time when misoprostol was administered vaginally (through March 20

183 Misoprostol was also associated with a decrease in mean

184 Oral misoprostol was associated with a significant reduction

185 ivariable analysis, use of mifepristone plus misoprostol was associated with decreased odds of subseq

186 Oral misoprostol was associated with significant decreases in

187 The effect of the stable PGE analog misoprostol was evaluated in a murine model of rheumatoi

188 Treatment with mifepristone plus misoprostol was more effective than misoprostol alone in

189 INTERPRETATION: Oral misoprostol was more effective than transcervical Foley

190 Diclofenac + misoprostol was rated as "better" or "much better" by 57

191 oglobin concentrations, neither oxytocin nor misoprostol was significantly better than the other, and

192 This trial established whether sublingual misoprostol was similarly efficacious to intravenous oxy

193 ugh an in-person screening, mifepristone and misoprostol were prescribed using a mail-order pharmacy.

194 ifepristone (also known as RU-486) used with misoprostol were reported.

195 ologic agents, such as PGE2, PGF2 alpha, and misoprostol, were applied topically to the eye.

196 These immunosuppressive effects of misoprostol, which were not shared by mifepristone, corr

197 ts CML LSCs and that the combination of PGE1/misoprostol with conventional tyrosine-kinase inhibitors

198 ge, typically involves the administration of misoprostol with or without pretreatment with mifepristo

199 Patients who received misoprostol with pretreatment with mifepristone were les

200 00 mug of mifepristone and up to 1600 mug of misoprostol without additional intervention, and major a

201 Clinical equivalence of misoprostol would be accepted if the upper bound of the

202 ted whether treatment with mifepristone plus misoprostol would result in a higher rate of completion